Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells $506,500.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $20.26, for a total transaction of $506,500.00. Following the completion of the transaction, the director directly owned 797,652 shares in the company, valued at approximately $16,160,429.52. The trade was a 3.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CeriBell Stock Performance

Shares of CBLL opened at $20.93 on Friday. The firm has a market capitalization of $776.50 million, a P/E ratio of -13.86 and a beta of 1.35. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $29.96. The stock has a 50 day moving average price of $14.32 and a two-hundred day moving average price of $14.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. Equities analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the last quarter. Yu Fan lifted its stake in CeriBell by 10.7% in the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after purchasing an additional 130,964 shares during the last quarter. Novo Holdings A S grew its holdings in CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after purchasing an additional 20,000 shares during the period. TimesSquare Capital Management LLC increased its position in CeriBell by 2.6% in the third quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock worth $9,395,000 after buying an additional 20,700 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of CeriBell by 41.8% in the third quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock valued at $7,657,000 after buying an additional 196,299 shares during the period.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. TD Cowen reduced their price objective on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. JPMorgan Chase & Co. decreased their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Raymond James Financial assumed coverage on CeriBell in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 target price on the stock. Finally, Cowen reaffirmed a “buy” rating on shares of CeriBell in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.17.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.